|1.||Adelstein, Robert S: 5 articles (05/2015 - 09/2003)|
|2.||Betapudi, Venkaiah: 4 articles (01/2014 - 05/2006)|
|3.||Bond, Jennifer E: 3 articles (12/2015 - 01/2011)|
|4.||Levinson, Howard: 3 articles (12/2015 - 01/2011)|
|5.||Lombardi, Vincenzo: 3 articles (10/2013 - 11/2002)|
|6.||Turner, Jerrold R: 3 articles (08/2013 - 10/2005)|
|7.||Bresnick, Anne R: 3 articles (02/2012 - 05/2006)|
|8.||DiSanto, Michael E: 3 articles (01/2012 - 01/2011)|
|9.||Melman, Arnold: 3 articles (01/2012 - 10/2009)|
|10.||Zhang, Xinhua: 3 articles (01/2012 - 01/2011)|
10/01/2009 - "Coupled with our in vivo data in which nanomole doses of BLEB significantly increase ICP, our data substantiates an important role for the SM contractile apparatus in the molecular mechanism for EF and suggests the possibility of BLEB binding at myosin II as a therapeutic treatment for ED by targeting SM contractile pathways."
02/12/2015 - "Progenitor cells can be reversibly transformed into stable-bleb cells irrespective of their primary fate and motile characteristics by increasing myosin II activity through biochemical or mechanical stimuli. "
03/01/2011 - "At the sides of the cell, MLCK and myosin II localized to swelling-induced membrane blebs with actin just before retraction, and MLCK inhibition led to persistent blebbing and attenuated cell volume recovery. "
01/01/2011 - "We hypothesize BLEB inhibition of myosin II as a novel contraction protein targeted strategy to regulate DO. "
03/01/2008 - "In extreme cases, this can give rise to a traveling wave around the cell periphery, known as "circus movement." When growth stalls, an actin cortex reforms under the bleb membrane, and retraction starts, driven by myosin-II. Using flicker spectroscopy, we find that retracting blebs are fivefold more rigid than expanding blebs, an increase entirely explained by the properties of the newly formed cortical actin mesh. "
|2.||Wounds and Injuries (Trauma)
11/16/2010 - "Experimental results with this assay suggest that cell migration in the presence of cell debris is a two step process requiring (1) non-muscle myosin II-dependent cell clearance followed by (2) cell migration into newly cleared wound areas. "
12/01/2015 - "Mechanisms by which fibroblasts promote wound contraction may include activation of contractile signaling pathways, which promote interaction between non-muscle myosin II and ACTB and ACTG1. "
01/01/2014 - "The wounds were repaired even in myosin II null cells to a comparable degree as the wild-type cells, suggesting that myosin II does not contribute to wound repair. "
01/01/2014 - "Previous reports have shown that actin and myosin II accumulate around the wound and that the constriction of this purse-string closes the membrane pore. "
01/01/2014 - "Myosin II does not contribute to wound repair in Dictyostelium cells."
08/01/2013 - "Similarly, long MLCK(-/-) mice had limited increases in myosin II light chain phosphorylation, claudin-2 expression, and intestinal permeability and delayed onset of adoptive transfer-induced colitis. "
01/01/2015 - "The non-muscle-myosin-II heavy chain Myh9 mediates colitis-induced epithelium injury by restricting Lgr5+ stem cells."
10/01/2006 - "Colitis induced in vivo by adoptive transfer of CD4(+)CD45RB(hi) T cells was associated with increased epithelial MLCK expression and myosin II regulatory light chain (MLC) phosphorylation as well as morphologic tight junction disruption. "
08/01/2013 - "Induction of immune-mediated colitis by CD4(+)CD45RB(hi) adoptive transfer increased intestinal permeability, epithelial expression of claudin-2, the long isoform of MLCK, and TNFR2 (but not TNFR1) and phosphorylation of the myosin II light chain. "
|4.||Overactive Urinary Bladder (Overactive Bladder)
01/01/2011 - "OBJECTIVE To investigate the in vitro and in vivo effects of blebbistatin (a small cell-permeable molecule with high affinity and selectivity toward the myosin II contractile molecule) on bladder smooth muscle (SM) contractility, as antimuscarinic therapy is only 65-75% effective in treating overactive bladder (OAB) and is associated with considerable side-effects, with a < 25% continuation rate at 1 year. "
02/01/2011 - "In this study, we show that the morphology of tumor epithelial cells cultured on nanorods is rounded compared to flat surfaces and associated with decreased cellular stiffness and non-muscle myosin II phosphorylation. "
02/03/2015 - "Overall, 4-HAP modifies nonmuscle myosin II-based cell mechanics across phylogeny and disease states and provides proof of concept that cell mechanics offer a rich drug target space, allowing for possible corrective modulation of tumor cell behavior. "
02/01/2014 - "These observations position myosin II-dependent force generation and mechanotransduction at the crossroads between normal development and cancer. "
02/01/2014 - "Mechanical events dependent on myosin II also participate in tumor cell proliferation, invasion, and metastatic dissemination. "
02/01/2014 - "Myosin II in mechanotransduction: master and commander of cell migration, morphogenesis, and cancer."
|2.||Protein Isoforms (Isoforms)
|4.||Adenosine Triphosphatases (ATPase)
|5.||Nonmuscle Myosin Type IIA
|6.||Proteins (Proteins, Gene)
|7.||Epidermal Growth Factor (EGF)
|10.||Platelet-Derived Growth Factor
|2.||Drug Therapy (Chemotherapy)